GlaxoSmithKline Inc. Sustainability Profile
GlaxoSmithKline Inc. (GSK), a leading global healthcare company, is headquartered in California and operates extensively across North America, Europe, and Asia. Founded in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, GSK has established itself as a key player in the pharmaceutical and biotechnology sectors, focusing on research and development in vaccines, pharmaceuticals, and consumer healthcare products. GSK's core offerings include innovative medicines for respiratory, HIV, and oncology treatments, as well as a robust portfolio of vaccines and consumer health products. The company is renowned for its commitment to scientific excellence and patient-centric solutions, which have positioned it among the top pharmaceutical firms worldwide. With a strong emphasis on sustainability and access to healthcare, GSK continues to achieve significant milestones in improving global health outcomes.
DitchCarbon Score
How does GlaxoSmithKline Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
GlaxoSmithKline Inc.'s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
As of the latest reporting, GlaxoSmithKline Inc. does not provide specific carbon emissions data, indicating a lack of available figures for the most recent year. The company is a current subsidiary of GSK plc, which may influence its climate commitments and emissions reporting. GSK plc has established various climate initiatives that GlaxoSmithKline Inc. adheres to, including targets set through the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP). These initiatives aim to enhance transparency and accountability in emissions reduction efforts. While specific reduction targets for GlaxoSmithKline Inc. are not detailed, the overarching commitments from GSK plc suggest a focus on significant reductions in greenhouse gas emissions across all scopes. The company is involved in initiatives such as RE100, which promotes the transition to 100% renewable electricity, and the Climate Pledge, which underscores its commitment to climate action. In summary, while GlaxoSmithKline Inc. does not currently report specific emissions data, it is aligned with the broader climate strategies and commitments of its parent company, GSK plc, which are designed to address climate change and reduce carbon footprints effectively.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 1,040,928,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 788,149,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 16,630,521,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - |
How Carbon Intensive is GlaxoSmithKline Inc.'s Industry?
How Carbon Intensive is GlaxoSmithKline Inc.'s Location?
GlaxoSmithKline Inc.'s Scope 3 Categories Breakdown
GlaxoSmithKline Inc.'s Scope 3 emissions, which decreased by 0% last year and decreased by approximately 46% since 2013, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Use of Sold Products" being the largest emissions source at 56% of Scope 3 emissions.
Top Scope 3 Categories
GlaxoSmithKline Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
GlaxoSmithKline Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
